GLP-1 pills are coming, and they could revolutionize weight-loss …
Sep 17, 2024 · At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing.
GLP-1 RAs efficacious for weight loss in overweight, obesity …
7 hours ago · Retatrutide (12 mg once weekly) resulted in weight loss of up to 22.1% after 48 weeks; other novel single and combination GLP-1 agents were also efficacious. Adverse events were frequent (80 to 97 ...
GLP-1 RAs Efficacious for Weight Loss in Obesity Without Diabetes
12 hours ago · TUESDAY, Jan. 7, 2025 (HealthDay News) -- For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight loss, according to a review published online Jan. 7 in the Annals of Internal Medicine.. Areesha Moiz, from McGill University in Montreal, and colleagues examined the efficacy and safety of GLP-1 RAs and co-agonists ...
Many people using GLP-1s for weight loss stop treatment too soon ... - CNN
May 21, 2024 · An analysis of health insurance claims released Tuesday found that most people using GLP-1 medications – about 58% – were on their treatment plan for less than 12 weeks, falling short of a key...
Beyond Ozempic: New GLP-1 drugs promise weight loss and …
Drug companies are racing to develop GLP-1 drugs following the blockbuster success of Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound. Some of the experimental drugs may...
GLP-1 nonresponders: Up to 1 in 5 people don't lose weight | AP News
Nov 23, 2024 · In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of …
In new trial, Zepbound bests Wegovy for weight loss - UPI.com
Dec 4, 2024 · Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.
Top GLP-1 Agonists Balance Weight Loss Efficacy, Safety
1 day ago · Moiz A, Filion KB, Toutounchi H, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes. Ann Intern Med . Published online January 6 ...
GLP-1 Agonists: The Latest Obesity Long-Term Use Data
Nov 4, 2024 · The study results showed that treatment with once-weekly subcutaneous semaglutide was associated with clinically impactful and sustained weight loss of 15.2% at week 104, along with improvements in weight-related cardiometabolic risk factors.
As many as 1 in 5 people won't lose weight with GLP-1 drugs ... - CBS News
Nov 25, 2024 · About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to several obesity experts.
- Some results have been removed